CAR-based therapies: opportunities for immuno-medicine beyond cancer.
Nat Metab
; 4(2): 163-169, 2022 02.
Article
em En
| MEDLINE
| ID: mdl-35228742
ABSTRACT
One of the most exciting new therapies for cancer involves the use of autologous T cells that are engineered to recognize and destroy cancerous cells. Patients with previously untreatable B cell leukaemias and lymphomas have been cured, and efforts are underway to extend this success to other tumours. Here, we discuss recent studies and emerging research aimed to extend this approach beyond oncology in areas such as cardiometabolic disorders, autoimmunity, fibrosis and senescence. We also summarize new technologies that may help to reduce the cost and increase access to related forms of immunotherapy.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Receptores de Antígenos Quiméricos
/
Neoplasias
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article